This clinical oversight mirrors in-person carethe only difference is convenience and cost, not safety or accountability
Blum K, Thanos PK, Gold MS
This NMA shows that Tirzepatide delivers the strongest overall profile, followed closely by Semaglutide, while Liraglutide balances efficacy with the lowest risk of hypoglycemia
Continuous, non-pulsatile GH elevation is actually a problem: sustained receptor activation leads to desensitization and blunted response
[DOI] [PMC free article] [PubMed] [Google Scholar] 33.Xu X.-N., Jiang Y., Yan L.-Y., Yin S.-Y., Wang Y.-H., Wang S.-B., Fang L.-H., Du G.-H
In early-phase trials, patients receiving doses at or around 1 mg showed weight reductions ranging from 4% to 8% of baseline body weight over 12 weeks, with continued loss extending into longer study periods